• Imugene receives A$5.8m R&D tax refund for 2024 financial year
• Refund received as part of Australian Government's R&D tax incentive
• Refund will enable further clinical development of Imugene's immuno-oncology pipeline

Imugene Limited, a clinical-stage immuno-oncology company, has received its research and development (R&D) tax refund for the 2024 financial year, totalling A$5,872,248, including $84,990 interest. The refund is received as part of the Australian Government's R&D tax incentive, which provides companies engaging in appropriate and eligible activities with a refundable tax offset of up to 48.5%. The refund received by Imugene will enable the further clinical development of its immuno-oncology pipeline, which includes an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) targeting CD19 to treat blood cancers, multiple immunotherapy B-cell vaccine candidates, and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T's for solid tumours. Imugene is supported by a leading team of international cancer experts with extensive experience in developing novel cancer therapies that are currently marketed globally, and the company is well-funded and resourced to deliver on its commercial and clinical milestones.